Hong Kong Journal of Nephrology
Volume 8, Issue 2 , Pages 71-74, October 2006

Characteristic Changes in Anti-erythropoietin Antibodies in a Peritoneal Dialysis Patient Who Developed Pure Red Cell Aplasia

  • Shu-Hong Bi

      Affiliations

    • Division of Nephrology, Peking University First Hospital, Beijing, P.R. China
    • Division of Nephrology, Peking University Third Hospital, Beijing, P.R. China
    • ,
  • Li-Tao Cheng

      Affiliations

    • Division of Nephrology, Peking University First Hospital, Beijing, P.R. China
    • ,
  • Wei Chen

      Affiliations

    • Division of Nephrology, Peking University First Hospital, Beijing, P.R. China
    • Division of Nephrology, Peking University Third Hospital, Beijing, P.R. China
    • ,
  • Tao Wang

      Affiliations

    • Division of Nephrology, Peking University First Hospital, Beijing, P.R. China
    • Division of Nephrology, Peking University Third Hospital, Beijing, P.R. China
    • Corresponding Author InformationAddress correspondence and reprint requests to: Dr. Tao Wang, Division of Nephrology, Third Hospital, Peking University, 49 North Garden Road, Haidian District, Beijing 100083, P.R. China. Fax: (+86) 10-82907314

Article Outline

Although cases of anti-erythropoietin (anti-EPO) antibody-induced pure red cell aplasia (PRCA) have been reported since 1998, the role of anti-EPO antibodies in the development of PRCA is controversial, with many conflicting opinions. Here, we present a patient who had serial serum anti-EPO antibody levels measured both before and after the development of PRCA to observe the relationship between serial changes in anti-EPO antibody and hemoglobin levels. Enzyme-linked immunosorbent assays were used for the detection of anti-EPO antibodies. The patient's serum anti-EPO antibody levels showed a characteristic change over time: negative before the development of PRCA, strongly positive when PRCA was diagnosed, decreasing after receiving prednisone, and eventually became negative. More importantly, an inversely close association between changes in serum anti-EPO antibody and hemoglobin levels was shown. The characteristic changes in this case indicate that anti-EPO antibody might have a role in the development of PRCA, and monitoring the titer of anti-EPO antibody may be of great value in the diagnosis and treatment of PRCA.

Key words:  anemia , antibody , erythropoietin , pure red cell aplasia

No full text is available. To read the body of this article, please view the PDF online.

 

Back to Article Outline

References 

  1. Eckardt KU , Casadevall N . Pure red-cell aplasia due to anti-erythropoietin antibodies . Nephrol Dial Transplant . 2003;18:865–869
  2. Schellekens H . Immunogenicity of therapeutic proteins: clinical implications and future prospects . Clin Ther . 2002;24:1720–1740
  3. Casadevall N , Nataf J , Viron B , Kolta A , Kiladjian JJ , Martin-Dupont P , et al.   Pure red-cell aplasia and anti-erythropoietin antibodies in patients treated with recombinant erythropoietin . N Engl J Med . 2002;346:469–475
  4. Kharagjitsingh AV , Korevaar JC , Vandenbroucke JP , Boeschoten EW , Krediet RT , Daha MR , et al.   Incidence of recombinant erythropoietin (EPO) hyporesponse, EPO-associated antibodies, and pure red cell aplasia in dialysis patients . Kidney Int . 2005;68:1215–1222
  5. Wu G , Wadgymar A , Wong G , Ting R , Nathoo B , Mendelssohn D , et al.   A cross-sectional immunosurveillance study of anti-EPO antibody levels in CRF patients receiving epoetin alfa in 5 Ontario Renal Centers . Am J Kidney Dis . 2004;44:264–269
  6. Mayeux P , Billat C , Jacquot R . The erythropoietin receptor of rat erythroid progenitor lens. Characterization and affinity cross-linkage . J Biol Chem . 1987;262:13985–13990
  7. Asari A , Gokal R . Pure red cell aplasia secondary to epoetin alpha responding to Darbepoetin alpha in a patient on peritoneal dialysis . J Am Soc Nephrol . 2004;15:2204–2207
  8. Chng WJ , Tan LK , Liu TC . Cyclosporine treatment for patients with CRF who developed pure red blood cell aplasia following EPO therapy . Am J Kidney Dis . 2003;41:692–695
  9. Mandreoli M, Finelli C, Lopez A, Ascani S, Vianelli N, Baccarani M, et al. Successful resumption of epoetin alfa after rituximab treatment in a patient with pure red cell aplasia . Am J Kidney Dis . 2004;44:757–761
  10. Kadikoylu G , Bolaman Z , Barutca S . High-dose methylprednisolone therapy in pure red cell aplasia . Ann Pharmacother . 2002;36:55–58

PII: S1561-5413(09)60236-2

doi:10.1016/S1561-5413(09)60236-2

Hong Kong Journal of Nephrology
Volume 8, Issue 2 , Pages 71-74, October 2006

Article Tools